<DOC>
	<DOCNO>NCT02560974</DOCNO>
	<brief_summary>This study compare capecitabine/oxaliplatin adjuvant chemotherapy versus observation alone chemotherapy-naive participant undergone potentially curative resection gastric cancer . Participants randomize either chemotherapy arm observation arm . Capecitabine administer orally , 1000 milligram per meter-squared ( mg/m^2 ) twice daily ( BID ) Days 1 15 3-week cycle , 8 cycle , oxaliplatin administer intravenous ( IV ) infusion , 130 mg/m^2 every 3 week 8 cycle . The anticipated time study treatment 6 month target sample size 1024 individual .</brief_summary>
	<brief_title>A Study Capecitabine ( Xeloda ) Combination Chemotherapy Versus Surgery Alone Participants With Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Adult participant great equal ( &gt; = ) 18 year age Gastric adenocarcinoma , Stage II , IIIa IIIb Potentially curative resection tumor within 6 week prior randomization Previously untreated chemotherapy radiotherapy Serious concomitant medical illness would limit life expectancy le ( &lt; ) 5 year Sexually active male female ( childbearing potential ) unwilling practice contraception study Any evidence metastatic disease ( include presence tumor cell ascites )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>